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A 72-year-old woman with sick sinus syndrome (SSS), who had frequent paroxysmal atrial
ﬁbrillations (PAfs) and normal cardiac function, was admitted to our hospital due to syncope.
PAfs frequently occurred during the ﬁrst week after DDD pacemaker implantation (PMI),
with closed loop stimulation (CLS) rate-adaptive mode oﬀ, but were completely suppressed
during the second week, with CLS on, and had been well-controlled over three years
thereafter. However, PAfs occasionally occurred under intense sympathetic activity during 6
months after PMI as well, and were eﬀectively terminated by disopyramide which had
anticholinergic eﬀect. Thus, the development and maintenance of PAf were thought to be
associated with destabilized cardiac autonomic activities, that is, sympathetic and para-
sympathetic dominance, respectively. Additionally, heart rate variability analyses after
implementation of CLS revealed the restoration of sympathetic and parasympathetic
components. Accordingly, CLS mode was considered to play a critical role in preventing
PAf by reﬂecting autonomic activity in heart rhythm in this SSS patient.
(J Arrhythmia 2009; 25: 158–164)
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Various physiological and rate-responsive pacing
modes for sick sinus syndrome (SSS) patients have
been developed. Either AAI or DDD pacing mode is
generally thought to be more physiological and
appropriate than VVI. Recent studies reported that
these physiological pacing modes prevented atrial
ﬁbrillation (Af) in bradycardia patients.1,2) More
recently, the eﬀect of minimal ventricular pacing
(MVP) to reduce the development to chronic atrial
ﬁbrillation (CAf) has been reported.3) On the other
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hand, various rate-responsive modes have been
studied to search for the most physiological and
Af-preventive mode.4)
The cardiac autonomic nerve controls cardiac
output by inotropic and chronotropic action. The
inotropic action is thought to be reﬂected in the
electrical impedance of cardiac muscle during the
systolic phase. Actually, the impedance gauged
between the tip of ventricular pacemaker lead and
the generator during the systolic phase in every
single cardiac cycle was reported to be intimately
related to the cardiac autonomic activity.5) Pace-
makers adopting impedance as a marker of the
autonomic activity which is applied to the rate-
responsive mode have appeared in clinical settings.
The rate-responsive mode is refered to as closed loop
stimulation (CLS).
The CLS system monitors the beat-by-beat im-
pedance changes during the systolic phase, calcu-
lates the chronotropic signals corresponding to the
impedance, and then almost instantly utilizes the
signals for subsequent pacing intervals. The regu-
lation of heart rate and rhythm by the cardiac
autonomic nerve have deteriorated in SSS patients.
The reconstruction by means of a CLS system of the
deteriorated feedback loop of chronotropic action in
SSS seems to lead to physiological and adequate
heart rate modulation. Recently, this rate-adaptive
mode was shown to be possibly eﬀective in
suppressing paroxysmal atrial tachycardia burden.6)
However, as far as we are aware, there are few case
reports which showed that CLS mode had obvious
beneﬁt in preventing paroxysmal atrial ﬁbrillation
(PAf) in SSS patients, even with antiarrhythmic
agents. We observed distinct immediate and long-
term eﬀectiveness of CLS mode along with drug
administration in preventing frequently repetitive
development of PAfs in an SSS case.
Case report
A 72-year-old woman with hypertension began to
feel palpitations in September 2003 and her general
practitioner diagnosed PAf. She was prescribed
disopyramide (100mg) as needed in the event of a
PAf attack. PAfs occurred as frequently as 10 to 20
times per month and continued for several hours,
but were usually terminated with disopyramide
within the same day. By mid-November, PAfs
started to occur every 2 days and lasted longer.
She was then prescribed 300mg of disopyramide
daily. On December 4, palpitations started and
continued until the afternoon on the following day,
when syncope occurred immediately after a few
occurrences of near syncope subsequent to deliver-
ing a speech at a meeting in her oﬃce. By the time
an ambulance arrived 10 minutes later, she had
recovered from the syncope. She was subsequently
admitted to our hospital for further examination and
therapy.
Upon admission, her pulse was regular bradycar-
dia and blood pressure was 119/40mmHg. Blood
chemistry proﬁles, electrolytes, thyroid function and
catecholamines were normal except for slight liver
dysfunction. Electrocardiography (ECG) showed
sinus bradycardia of 55 bpm. Chest X-ray and
echocardiographic ﬁndings were essentially normal.
Holter monitoring revealed 65,972 total heart beats
per 24 hours, which conﬁrmed extreme sinus
bradycardia, and pauses of about 2 seconds in
blocked atrial premature beats. Electrocardiographic
monitoring in the ward showed repeated PAf attacks
and a maximal pause of 8.7 seconds on conversion to
sinus rhythm. The PAfs always spontaneously con-
verted to sinus rhythm; however, the temporary use
of ﬂecainide, pilsicainide, aprindine or disopyramide
had no eﬀect immediately after admission. The
patient was given 8mg per day of candesartan, an
angiotensin II receptor antagonist with some evi-
dence of suppressing Af, to replace ormesaltan
(20mg) which had been prescribed for hypertension
before admission. Aprindine (60mg) daily was
added after admission (Figure 1A).
On December 21, the patient was implanted with a
rate-adaptive pacemaker with a CLS mode (Protos
DR/CLS; BIOTRONIK; Germany). The pacemaker
parameters were as follows: On implantation, pace-
maker was programmed for DDD mode, 60 bpm
basic pacing rate and 150msec AV delay. Then, one
week after PMI, CLS rate-responsive mode was
added and at the same time the 150msec AV delay
was changed to the dynamic AV delay, ranging as
follows according to heart rate: AV delay 160msec:
HR<70 bpm, 150msec: 70–90 bpm, 140msec: 91–
110 bpm, 120msec: 111–130 bpm, 100msec: >130
bpm. As this patient worried about recurrence of
PAfs, she had stayed in a sedentary or supine
position in her bed throughout hospitalization. Thus,
the pacemaker continued DDD pacing at a basic rate
of 60 bpm during the ﬁrst week after PMI. Even if
the dynamic AV delay had been applied from the
ﬁrst week, the AV delay corresponding to a basic
rate would have been 160msec, which would have
diﬀered only by 10msec from the 150msec AV
delay actually applied during the ﬁrst week. The
10msec diﬀerence would not have inﬂuenced the
suppressive eﬀect on PAf or heart rate variability
much.
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On the day after PMI, atenolol (25mg),  blocker,
which was reduced to 12.5mg on discharge because
of disappearance of PAfs as well as bradycardia due
to SSS, and warfarin (3mg) daily were added for the
rate control and anticoagulant therapy in case of PAf
attack, respectively. Although PAfs occurred during
the ﬁrst week after PMI without CLS function as
frequently as before PMI or admission, those were
completely suppressed during the 2nd week after
PMI with the CLS function on (Figure 1A,2). During
hospitalization, PAf attacks documented by ECG
monitoring coincided well with her symptom of
palpitation. After the application of CLS, a 100mg
bolus of disopyramide or a 200mg per os of it as
needed became remarkably eﬀective against the
PAf, the frequency and length of which gradually
decreased (Figure 1B,2). In 6 months after discharge.
The patient remained almost free of PAf subjectively
as well as objectively over more than three years to
date (Figure 2), even after aprindine was withdrawn
on October 12, 2006, although the data from
pacemaker clinic between May 25 and September
15, 2006 were missing.
The PAf in this patient seemed to develop in
association with increased sympathetic or mental
activity, such as immediately after delivering the
speech at her oﬃce or PMI in our hospital, on the
day of discharge or the ﬁrst day back to work after
discharge and when driving for a long time or
attending ceremonies. In addition, the anticholiner-
gic drug, disopyramide, terminated the PAf ex-
tremely eﬀectively after PMI.
Holter monitoring was conducted on December 4,
2007, 2 years after PMI, and revealed almost all
heart beats were derived from atrial pacing with
intermittent atrio-ventricular sequential pacing
modulated by the CLS system throughout the day
(cf. Figure 2). Heart rate variability was calculated
using MemCalc, the software prepared by NIHON
KOHDEN Corp. Every single successive R wave
was manually labeled and all the RR intervals were
processed in chronological order for heart rate
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Figure 1 Duration and frequency of PAfs during hospitalization and after discharge
(A) ECG monitoring during hospitalization: PAf frequently occurred before implementation of CLS rate-adaptive mode even after PMI.
Administration of several kinds of antiarrhythmogenic agents as needed did not work as indicated by the middle arrow. However, PAf was
completely suppressed after the implementation of CLS. During hospitalization, PAf attacks documented by ECG monitoring coincided
well with her symptom of palpitation.
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variability analysis. Premature beats were eliminated
from the monitoring periods. Ultimately, 93,543
beats, 99.2% of total heart beats, were processed for
analysis. Power spectral analyses revealed that heart
rate variability derived from almost 100% of CLS
restored the high frequency (HF) [0.15–0.40Hz] and
low frequency (LF) [0.04–0.15Hz] components,
both of which meant autonomic activity, along with
very low frequency (VLF) [0.003–0.04Hz] and ultra
low frequency (ULF) [0.0001–0.003Hz] compo-
nents, and that each had distinct circadian rhythms
(Figure 3).
The question how heart rate variability was
analyzed at night when heart rate would decrease
to a basic heart rate of the pacemaker might be
raised. Fortunately, even at night or in the early
morning, mean heart rate maintained at 62 to
67 bpm, and heart rate ﬂuctuated around the mean
heart rate and only transiently, if ever, decreased
down to the basic heart rate. Actually, HF compo-
nent, the parameter of parasympathetic activity
calculated from Holter monitoring, showed prom-
inent increase at nighttime and clear circadian
rhythm. In addition, even if not so, because PAfs
tended to develop exclusively in the daytime, heart
rate variability in the daytime seemed crucial to the
suppressive eﬀect on PAf, but not as much in the
nighttime.
Discussion
We described a patient who had SSS, group III,
but normal cardiac function with repeated drug-
resistant PAfs, which was ﬁnally suppressed by a
pacemaker with the CLS rate-adaptive mode.
Although PAfs occurred during the ﬁrst week after
PMI without the CLS function as frequently as
before PMI, PAf attacks did not develop during the
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Figure 1
(B) Symptom and pacemaker memory after discharge: Although PAf attacks transiently increased shortly after discharge, probably due to
increased physical and mental activity, disopyramide, as needed, eﬀectively and obviously terminated PAf as indicated with arrows in the
middle. The duration and frequency gradually decreased during a period of 6 months immediately after discharge.
The shaded bars indicate the duration as well as frequency of PAfs according to ECG monitoring (A) and symptom (B) on the left Y axis.
The broken lines indicate the ratio of the total atrial sensing over 150 bpm to the total atrial sensing during the periods between each
successive pacemaker clinic visits on the right Y axis.
PMI: pacemaker implantation, PMC: pacemaker clinic, CLS: closed loop stimulation
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second week after PMI with the CLS on (Figure 1A).
Thus CLS seemed to suppress PAf attacks in the
short term. We have seldom experienced such
distinct on-and-oﬀ and immediate prophylactic
eﬀects of a rate-responsive mode of pacemaker
against PAfs in patients with SSS.
Lombardi F et al. showed that the LF/HF obtained
from heart rate variability analyses 4 to 5 hours after
electrical cardioversion was useful to predict the
short-term recurrence of PAf, and insisted that
autonomic activity was closely related to PAf
recurrence around 2 weeks after cardioversion.7)
Puglisi A et al. evaluated the suppressive eﬀect of
three kinds of pacemaker rate-responsive algorithms
on PAf, including conventional response, overdrive
pacing and CLS modes, and found that the CLS
mode eﬀectively suppressed PAf for 4 and 7 months
after PMI.6) They inferred that turbulent autonomic
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Figure 2 Memory data obtained from pacemaker
Based on memory data obtained from pacemaker clinic, the rates of ventricular and atrial pacing and atrial sensing more rapid than
150 bpm as surrogate marker of atrial ﬁbrillation are shown. The on-and-oﬀ prophylactic eﬀect of CLS against PAf attacks was obvious
during hospitalization after PMI. The tachycardia episodes in atrium gradually decreased until May 25, 2006, after abrupt recurrence
subsequent to discharge. Ventricular pacing rate was not necessarily proportionate to atrial tachycardia burden in this patient. The shaded
area indicates the period when the data were missing. PMI, PMC and CLS as were described in Figure 1.
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Figure 3 Heart rate variability modulated by CLS rate-adaptive mode
After almost 100% of atrial pacing modulated by CLS mode was veriﬁed by Holter monitoring, power spectral analyses of heart rate
variability were conducted. The result revealed that the components of HF, LF, VLF and ULF appeared in heart rate variability. HF
components increased in nighttime, whereas LF increased in daytime, which seemed to reﬂect circadian rhythms as well as beat-by-beat
modulation of cardiac autonomic activity.
HF: high frequency, LF: low frequency, VLF: very low frequency, ULF: ultra low frequency, PSD: power spectral density
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activity occurred immediately before PAf develop-
ment, and that the CLS algorithm played a critical
role in the time frame and thus reduced the PAf
burden.
In our patient, PAfs developed in the setting of
increased sympathetic activity, and, after PMI, were
easily terminated by disopyramide which had an
anticholinergic eﬀect. These phenomena implied
that the development and maintenance of atrial
ﬁbrillation in this patient were associated with
destabilized autonomic activity, probably with sym-
pathetic and parasympathetic dominance, respective-
ly. Moreover, Holter monitoring 2 years after PMI
showed that heart rhythm consisted of almost 100%
of atrial pacing rhythms controlled by the CLS
system throughout the day. Power spectral analyses
of heart rate variability revealed HF component
(vagal activity), LF component (sympathetic and
vagal activity), the LF/HF ratio (sympathovagal
balance or sympathetic activity), and their clear
circadian rhythms (Figure 3). These ﬁndings suggest-
ed that the CLS system captured the dynamics of
beat-by-beat and daily cardiac autonomic activity
through electrical impedance of cardiac muscle and
indeed realized the natural and physiological heart
rate and rhythm modulation.
The prompt prophylactic eﬀect immediately after
implementation of CLS during the second week after
PMI was attributable to the heart rate modulation
based on the real-time cardiac autonomic activities
by controlling heart rate variability beat by beat as
well as improving bradycardia itself. It was also
possible that  blocker administration would modify
the abrupt excessive sympathetic activity in this
patient. The reason PAf almost completely disap-
peared in the end could be that the PAf duration was
shortened due to the immediate eﬀect of disopyr-
amide after PMI. In addition, the use of angiotensin
II antagonist might have led to reverse electrical
remodeling in the atrial muscle in the long term.
On the other hand, the randomized comparison of
VVI and AAI pacing by Connolly SJ et al. found that
the annual rate of Afs was signiﬁcantly lower among
patients with physiological AAI pacing than among
those with VVI.8) However, they also noted that the
beneﬁt of the physiological pacing did not become
apparent until 3 years of follow-up. Sweeney MO
et al. implanted DDD pacemakers in patients with
bradycardia, 38% of whom had a histories of PAf.
Their prospective comparative study (dual-chamber
MVP vs. conventional dual-chamber pacing; ven-
tricular pacing rate: 9.1% vs. 99.0%) demonstrated
that the conversion rate into CAf was lower by 40%
in the patients with MVP than with conventional
pacing.3) They concluded that dual-chamber MVP
suppressed the development of CAf. However, CAf
still developed in the rest (60%) of the patients who
received the dual-chamber MVP. The CLS algorithm
might have prevented CAf developing in some of
them.
We ﬁrst implanted a pacemaker with DDD mode
in our patient, and then changed the pacing mode
to DDD-CLS rate-adaptive mode one week later
(Figure 1A). In reality, DDD-dominant pacing and
AAI-dominant pacing were conducted during the
ﬁrst week and the second week after PMI, respec-
tively (Figure 2). PAf was clearly suppressed during
the 2nd week, and not the 1st week. However, over
more than three years after PMI, ventricular pacing
rate had ﬂuctuated between 15% and 83%, whereas
the total amount of atrial sensing more rapid than
150 bpm, which was regarded as the surrogate
marker of PAf, was disproportionate to the ventric-
ular pacing rate (Figure 2). Thus, with respect to this
case, we supposed that the immediate and on-and-oﬀ
suppressive eﬀect against PAf attack might be
attributed to the implementation of CLS, not to the
reduction in ventricular pacing rate.
The limitations of this case report are given as
follows: Since the suppressive eﬀects of physiolog-
ical pacing appear at various times after PMI
depending on individuals,9) the clinical course of
this case might be peculiar to this individual, not to
the CLS rate-responsive mode. Additionally, the
natural course might have happened to coincide with
the date of PMI. There are also several reports that
DDD pacing even without rate-responsive mode
suppressed PAfs. Accordingly, if possible, we need
to conﬁrm the reproducibility of the suppressive
eﬀect of the CLS mode on PAf in this patient by
suspending CLS mode, or by conducting PMI with
CLS rate-responsive mode in similar patients. How-
ever, this patient is doing well under the current
condition of the pacemaker parameters, has been
essentially free from PAf over more than three years,
and is now in the process of withdrawing anti-
coagulant therapy. Therefore, it was diﬃcult from an
ethical point of view to verify the reproducibility. It
was also true that this kind of case is quite rare.
In conclusion, we implanted a pacemaker into a
patient with SSS, group III, whose cardiac function
was normal yet who had recurrent PAfs under
intense sympathetic activity. The CLS rate-respon-
sive mode along with a daily  blocker elicited the
obvious on-and-oﬀ prophylactic phenomenon of PAf
shortly after PMI. The occasional administration of
disopyramide was extremely eﬀectively in terminat-
ing PAf attacks and then reduce the duration and
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frequency in 6 months after PMI and thereafter the
patient remains essentially free of PAf without
disopyramide for more than three years. In addition,
heart rate variability analyses after PMI showed the
restoration of sympathetic and parasympathetic
components manipulated by CLS mode. According-
ly, CLS rate-adaptive mode along with -blocker
was thought to play a critical role in prophylaxis of
PAf attack by reﬂecting autonomic activity in heart
rhythm in this patient with SSS, group III, and
normal cardiac function.
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